| scholarly article | Q13442814 |
| P50 | author | Dai Wang | Q41839537 |
| Adam C Finnefrock | Q57384780 | ||
| P2093 | author name string | Danilo R Casimiro | |
| Aimin Tang | |||
| Daniel C Freed | |||
| Tong-Ming Fu | |||
| Fengsheng Li | |||
| Shannon N Grimes | |||
| P2860 | cites work | A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant | Q78231630 |
| Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease | Q83256501 | ||
| Vaccine prevention of maternal cytomegalovirus infection | Q24645631 | ||
| Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex | Q33558361 | ||
| Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study | Q33880835 | ||
| High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. | Q33913596 | ||
| Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism | Q34212879 | ||
| Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells | Q34885758 | ||
| Pathogenesis of human cytomegalovirus infection and cellular targets | Q35789320 | ||
| Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells | Q36289031 | ||
| Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. | Q36423984 | ||
| Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection | Q36853713 | ||
| Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection | Q36973592 | ||
| Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome | Q37568012 | ||
| Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. | Q37774313 | ||
| Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. | Q39591457 | ||
| Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes | Q39960937 | ||
| Maternal immunity and prevention of congenital cytomegalovirus infection | Q40604196 | ||
| Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism | Q41839444 | ||
| Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. | Q45084505 | ||
| Safety and immunogenicity of the Towne strain cytomegalovirus vaccine | Q45110668 | ||
| Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. | Q45396472 | ||
| Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. | Q45406643 | ||
| The outcome of congenital cytomegalovirus infection in relation to maternal antibody status | Q50539344 | ||
| Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. | Q51889754 | ||
| Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection | Q55982678 | ||
| Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates | Q57275303 | ||
| Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells | Q57275307 | ||
| Large-scale testing of human serum to determine cytomegalovirus neutralising antibody | Q67489662 | ||
| Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells | Q67915468 | ||
| Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay | Q70147066 | ||
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| antibody | Q79460 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 9075-9080 | |
| P577 | publication date | 2011-09-22 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection | |
| P478 | volume | 29 |
| Q36888046 | A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers |
| Q36385141 | A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells. |
| Q33558900 | A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells |
| Q40474474 | A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. |
| Q38730422 | A two-step screening approach for the identification of blood donors with highly and broadly neutralizing capacities against human cytomegalovirus |
| Q36559845 | A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. |
| Q47135919 | Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection |
| Q91264520 | Analysis of relationships between polymorphisms in the genes encoding the pentameric complex and neutralization of clinical cytomegalovirus isolates |
| Q36155456 | Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin |
| Q37174327 | Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures |
| Q98195619 | Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes |
| Q42267802 | Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread |
| Q91736664 | Comparative neutralizing potencies of antibodies suggest conservation as well as mechanistic differences in human cytomegalovirus entry into epithelial and endothelial cells |
| Q38456515 | Complex correlates of protection after vaccination |
| Q36341023 | Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study |
| Q90271787 | Development of novel vaccines against human cytomegalovirus |
| Q42284386 | Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection |
| Q37545058 | Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity |
| Q89685617 | HCMV glycoprotein B nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gB protein immunization |
| Q55401180 | Human Macrophages Escape Inhibition of Major Histocompatibility Complex-Dependent Antigen Presentation by Cytomegalovirus and Drive Proliferation and Activation of Memory CD4+ and CD8+ T Cells. |
| Q42218132 | Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice |
| Q21089588 | Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex |
| Q47605886 | Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy |
| Q38708710 | Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells. |
| Q37120061 | In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. |
| Q60031666 | Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees |
| Q58738833 | Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread |
| Q38908361 | Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants. |
| Q27683850 | Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109 |
| Q37707461 | Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex. |
| Q37409489 | Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine |
| Q40480154 | Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta. |
| Q35859879 | Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults |
| Q37197051 | Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus |
| Q33877783 | Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. |
| Q38200419 | Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. |
| Q38629007 | RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells |
| Q35783065 | Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes |
| Q38384533 | The history of vaccination against cytomegalovirus |
| Q36694861 | Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. |
Search more.